“…TRB3 (alias TRIB3, NIPK, SKIP3), a member of the Tribbles family of pseudokinases, interacts with several transcription factors (ATF4 (Bowers et al, 2003;Örd and Örd, 2003), CHOP (Ohoka et al, 2005), NF-κB (Wu et al, 2003), C/EBPβ (Bezy et al, 2007)), protein kinases (Akt/PKB (Du et al, 2003), MAPK kinases MEK1 and MKK7 (Kiss-Toth et al, 2004)) and other proteins (E3 ubiquitin ligase COP1 (Qi et al, 2006), Smad ubiquitin regulatory factor 1 (Chan et al, 2007), nuclear protein CtIP (Xu et al, 2007)), and has been implicated in the regulation of cellular stress response, viability and metabolism. TRB3 has attracted attention for its potential role in medical conditions: molecular and epidemiologic studies, as well as the examination of disease models, have linked TRB3 to insulin resistance (Du et al, 2003;Koo et al, 2004;Prudente et al, 2005;He et al, 2006;Yao and Nyomba, 2008), cardiovascular disease (Prudente et al, 2005) and diabetes (Prudente et al, 2009), and the elevated expression of TRB3 has been reported in many cancer cell lines and primary tumors (Bowers et al, 2003;Xu et al, 2007), and in cancer cells treated with antitumoral agents (Carracedo et al, 2006a,b).…”